Market Research Logo

Ocular Therapeutix Inc (OCUL) - Product Pipeline Analysis, 2018 Update

Summary

Ocular Therapeutix Inc (Ocular), formerly I-Therapeutix Inc is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for diseases using hydrogel platform technology. The company’s products include DEXTENZA, sustained release travoprost and posterior segment injections. Its hydrogel technology uses polyethylene glycol to create ophthalmic sustained drug delivery systems. Ocular’s hydrogel provides containment, localization and protection from inflammatory response, and a material for sustained delivery of drugs to the eye. The company also provides ReSure Sealant, a ocular sealant proven in clinical trial to be safe in sealing clear corneal incisions following cataract surgery. Its products are used for the treatment of glaucoma and ocular hypertension, post-operative inflammation, allergic conjunctivitis, dry eye and retinal diseases. Ocular is headquartered in Bedford, Massachusetts, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Ocular Therapeutix Inc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company


Ocular Therapeutix Inc Company Overview
Ocular Therapeutix Inc Company Snapshot
Ocular Therapeutix Inc Pipeline Products and Ongoing Clinical Trials Overview
Ocular Therapeutix Inc – Pipeline Analysis Overview
Ocular Therapeutix Inc - Key Facts
Ocular Therapeutix Inc - Major Products and Services
Ocular Therapeutix Inc Pipeline Products by Development Stage
Ocular Therapeutix Inc Ongoing Clinical Trials by Trial Status
Ocular Therapeutix Inc Pipeline Products Overview
DEXTENZA
DEXTENZA Product Overview
OTX-IVT
OTX-IVT Product Overview
OTX-MP
OTX-MP Product Overview
OTX-TIC
OTX-TIC Product Overview
OTX-TIC Clinical Trial
OTX-TKI
OTX-TKI Product Overview
OTX-TP
OTX-TP Product Overview
OTX-TP Clinical Trial
Ocular Therapeutix Inc - Key Competitors
Ocular Therapeutix Inc - Key Employees
Ocular Therapeutix Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Ocular Therapeutix Inc, Recent Developments
Jul 19, 2018: Ocular Therapeutix Announces FDA Acceptance of NDA Resubmission for DEXTENZA
Jun 29, 2018: Ocular Therapeutix Announces NDA Resubmission of DEXTENZA
May 03, 2018: Ocular Therapeutix Announces Treatment of First Patient in Phase 1 Clinical Trial of OTX-TIC (travoprost intracameral implant) for the Treatment of Glaucoma and Ocular Hypertension
Apr 09, 2018: Ocular Therapeutix to Present Data at the American Society of Cataract and Refractive Surgery Symposium
Mar 08, 2018: Ocular Therapeutix Reports Fourth Quarter and Year End 2017 Financial Results and Business Update
Jan 08, 2018: Ocular Therapeutix Announces Kevin Hanley as Senior Vice President, Technical Operations and Naymisha Patel as Vice President of Quality
Dec 22, 2017: Ocular Therapeutix Provides Legal Update
Nov 07, 2017: Ocular Therapeutix Reports Third Quarter 2017 Financial Results and Provides Corporate Update
Sep 25, 2017: Ocular Therapeutix Appoints Donald Notman as Chief Financial Officer
Sep 08, 2017: Ocular Therapeutix Appoints Michael Goldstein, M.D., M.B.A., as Chief Medical Officer
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Ocular Therapeutix Inc Pipeline Products and Ongoing Clinical Trials Overview
Ocular Therapeutix Inc Pipeline Products by Equipment Type
Ocular Therapeutix Inc Pipeline Products by Indication
Ocular Therapeutix Inc Ongoing Clinical Trials by Trial Status
Ocular Therapeutix Inc, Key Facts
Ocular Therapeutix Inc, Major Products and Services
Ocular Therapeutix Inc Number of Pipeline Products by Development Stage
Ocular Therapeutix Inc Pipeline Products Summary by Development Stage
Ocular Therapeutix Inc Ongoing Clinical Trials by Trial Status
Ocular Therapeutix Inc Ongoing Clinical Trials Summary
DEXTENZA - Product Status
DEXTENZA - Product Description
OTX-IVT - Product Status
OTX-IVT - Product Description
OTX-MP - Product Status
OTX-MP - Product Description
OTX-TIC - Product Status
OTX-TIC - Product Description
OTX-TIC - To Evaluate the Safety, Efficacy, Durability, and Tolerability of OTX-TIC in Patients with Primary Open-angle Glaucoma or Ocular Hypertension
OTX-TKI - Product Status
OTX-TKI - Product Description
OTX-TP - Product Status
OTX-TP - Product Description
OTX-TP - Non-significant Risk Feasibility Study to Assess Retention and Replacement of the OTX Punctum Plug
Ocular Therapeutix Inc, Key Employees
Ocular Therapeutix Inc, Other Locations
Glossary
List of Figures
Ocular Therapeutix Inc Pipeline Products by Equipment Type
Ocular Therapeutix Inc Pipeline Products by Development Stage
Ocular Therapeutix Inc Ongoing Clinical Trials by Trial Status

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report